BioNxt Solutions Completes Up-Listing to The OTCQB Market
BioNxt Solutions (OTCQB:BNXTF) has successfully completed its up-listing from OTC to the OTCQB market, with trading commencing on September 5, 2025. The company will maintain its listing on the Canadian Securities Exchange under the symbol "BNXT".
CEO Hugh Rogers highlighted the company's progress, noting three proprietary sublingual drug development programs in Europe and an upcoming chemotherapy drug delivery deal in North America. The OTCQB up-listing is expected to increase visibility and accessibility to U.S. investors, with the company committing to regular financial disclosures and compliance with OTCQB standards.
BioNxt Solutions (OTCQB:BNXTF) ha completato con successo il passaggio dall'OTC all'OTCQB market, con l'avvio delle negoziazioni il 5 settembre 2025. La società manterrà la quotazione sulla Canadian Securities Exchange con il simbolo "BNXT".
Il CEO Hugh Rogers ha sottolineato i progressi dell'azienda, evidenziando tre programmi proprietari di sviluppo di farmaci sublinguali in Europa e un imminente accordo per la somministrazione di chemioterapia in Nord America. L'up-listing all'OTCQB dovrebbe aumentare la visibilità e l'accessibilità agli investitori statunitensi, con l'azienda impegnata a rendicontazioni finanziarie regolari e al rispetto degli standard OTCQB.
BioNxt Solutions (OTCQB:BNXTF) ha completado con éxito su subida de cotización de OTC al mercado OTCQB, iniciando negociaciones el 5 de septiembre de 2025. La compañía mantendrá su listado en la Canadian Securities Exchange con el símbolo "BNXT".
El CEO Hugh Rogers destacó los avances de la empresa, señalando tres programas propios de desarrollo de fármacos sublinguales en Europa y un próximo acuerdo de suministro de quimioterapia en Norteamérica. Se espera que la subida a OTCQB aumente la visibilidad y el acceso para inversores estadounidenses, y la compañía se compromete a divulgar información financiera periódica y a cumplir con los estándares de OTCQB.
BioNxt Solutions (OTCQB:BNXTF)는 OTC에서 OTCQB 시장으로의 상장 전환을 성공적으로 완료했으며, 2025년 9월 5일부터 거래를 시작했습니다. 회사는 캐나다증권거래소(CSE)에도 "BNXT" 심볼로 상장을 유지합니다.
CEO 휴 로저스(Hugh Rogers)는 유럽에서의 3개의 독점 설하(구강밑) 약물 개발 프로그램과 북미에서 예정된 항암제 전달 관련 계약을 언급하며 회사의 진전을 강조했습니다. OTCQB로의 상장은 미국 투자자들에 대한 가시성과 접근성을 높일 것으로 기대되며, 회사는 정기적인 재무 공시와 OTCQB 기준 준수를 약속했습니다.
BioNxt Solutions (OTCQB:BNXTF) a achevé avec succès sa montée de l'OTC vers le marché OTCQB, avec l'ouverture des négociations le 5 septembre 2025. La société conservera sa cotation à la Canadian Securities Exchange sous le symbole "BNXT".
Le PDG Hugh Rogers a mis en avant les progrès de l'entreprise, soulignant trois programmes propriétaires de développement de médicaments sublinguaux en Europe et un accord imminent pour la livraison de traitements chimiothérapeutiques en Amérique du Nord. Le passage à l'OTCQB devrait accroître la visibilité et l'accès aux investisseurs américains, la société s'engageant à publier des informations financières régulières et à respecter les normes OTCQB.
BioNxt Solutions (OTCQB:BNXTF) hat den erfolgreichen Wechsel von OTC zum OTCQB-Markt abgeschlossen; der Handel begann am 5. September 2025. Das Unternehmen wird weiterhin an der Canadian Securities Exchange unter dem Symbol "BNXT" notiert bleiben.
CEO Hugh Rogers hob die Fortschritte des Unternehmens hervor und wies auf drei proprietäre sublinguale Arzneimittelentwicklungsprogramme in Europa sowie einen bevorstehenden Vertrag zur Chemotherapie-Delivery in Nordamerika hin. Das OTCQB-Up-Listing soll die Sichtbarkeit und Zugänglichkeit für US-Investoren erhöhen; das Unternehmen verpflichtet sich zu regelmäßigen Finanzberichten und zur Einhaltung der OTCQB-Standards.
- None.
- None.
VANCOUVER, BC / ACCESS Newswire / September 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT), is pleased to announce that the common shares of the Company (the "Common Shares") shall commence trading on the OTCQB market under the ticker symbol "BNXTF" as of September 5, 2025. The upgrade from the Company's current OTC listing makes the Common Shares available to a larger group of US investors. The Company will continue to trade on the Canadian Securities Exchange under the symbol "BNXT".
"Up-listing BioNxt to the OTCQB is a strong endorsement of the Company's positive momentum," said Hugh Rogers, BioNxt CEO. "We've built a great platform over the past 12 months, both in terms of the capital markets and our product development pipeline. With three distinct and proprietary sublingual drug development programs underway in Europe and an exciting pending chemotherapy drug delivery deal here in North America, the Company is well positioned to delivery shareholder value over the next 12 months."
Per ongoing compliance requirements and in accordance with OTCQB listing standards, BioNxt will file periodic reports, disclosure, and the annual OTCQB certification. United States investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 604.250.6162
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward‐Looking" Information
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking information in this news release includes the statements regarding the filing of periodic reports and the improved liquidity and trading availability of the Common Shares. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
When will BioNxt Solutions (BNXTF) start trading on the OTCQB market?
What are BioNxt Solutions' (BNXTF) current drug development programs?
What stock exchanges does BioNxt Solutions (BNXTF) trade on?
What are the compliance requirements for BioNxt's OTCQB listing?
